Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
2020
Nothing magical about medicine prices
US puts pressure on the Netherlands over compulsory licenses
A busy week at the Court of Justice of the European Union
2019
How to measure change in EU Policy
Health Technology Assessments: will 2020 end the deadlock?
Is clinical trial transparency under threat?
REBRAND: Fact or Fiction publication
An insightful day at the EURIPID stakeholder meeting in Budapest
A Momentous Week for Access to Medicines
Dr Marg Ewen Receives the Helen Clark-JoPPP Award
No Universal Health Coverage without Universal Medicines Coverage
2018
A Year at the Heart of Regulatory Decision Making
Staff Spotlight: Jaume Vidal
Time for a Treaty? ReAct Reports on Second Consultation on Global Development & Stewardship Framework to Combat AMR
Medicijnen: de link met de maatschappij
What Role Can Civil Society Play in the European Regulatory Process?
Open Science for Health: Shaping the New Framework Programme
2017
EU-Mercosur Trade Agreement: A bad deal for transparency, policy coherence and access to medicines
New Dutch Government Must Ensure Transparency to Control Medicine Prices
Staff Spotlight: Tim Reed
European Commission Appoints Health Action International to HTA Network Stakeholder Pool
2016
Clinical Trial Data Transparency on Trial – EMA Under Pressure From Pharma Lawsuit
Next Gen Advocates Excel at HAI/HP4L Summer School on Access to Medicines
Farewell to Access to Medicines Pioneer, Andrew Herxheimer
2015
HAI/WHO Pharmaceutical Promotion Manual Still Key to Combating Promotion around the World
HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe
HAI urges MEPs to support key amendments to TTIP resolution
The EU-US Trade Deal Could Leave Europeans Sick
2014